Format

Send to

Choose Destination
Pediatr Blood Cancer. 2015 Aug;62(8):1477-80. doi: 10.1002/pbc.25467. Epub 2015 Mar 8.

Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.

Author information

1
The Harley Street Clinic, London, United Kingdom.
2
The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom.

Abstract

Previous chemotherapy and radiation exposure can make adequate stem cell mobilisation prior to autologous transplant extremely difficult in paediatrics. Plerixafor, a selective reversible CXCR4 antagonist interferes with CXCR4 interaction with Stromal cell-derived factor 1 alpha (SDF-1). Combination with granulocyte-colony stimulating factor (G-CSF) amplifies G-CSF affects in mobilising haematopoietic stem cells. Whilst licensed for use with G-CSF for enhancement of mobilisation of haematopoietic stem cells in adults, paediatric data for use of plerixafor remain limited. We present a retrospective review of outcomes seen with plerixafor and G-CSF to mobilise stem cells heavily pre-treated paediatric patients with cancer.

KEYWORDS:

CD34 positive stem cell; children; oncology; plerixafor; stem cell mobilisation

PMID:
25755177
DOI:
10.1002/pbc.25467
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center